Analyst Rating Update on XOMA Corporation (XOMA)

XOMA Corporation (XOMA) : 5 analysts are covering XOMA Corporation (XOMA) and their average rating on the stock is 2.6, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

XOMA Corporation (XOMA) stock is expected to deviate a maximum of $1.2 from the average target price of $1.62 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $3 and the most muted being $1.

Company shares have received an average consensus rating of Hold for the current week


XOMA Corporation (NASDAQ:XOMA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.65 and $0.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.66. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.65, notching a gain of 2.38% for the day. The total traded volume was 858,237 . The stock had closed at $0.63 on the previous day.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.